Crossject (ALCJ.PA) Aktie Kurs
Crossject Kurs
De seneste 14 år voksede Crossjects omsætning med 24,1 % årligt og nåede 4,12 Mio. EUR. For Crossject er nettoavance på -310,9 % ned i forhold til -203,2 % for et par år siden. Konsensus 12-måneders kursmål for Crossject er 4,39 EUR, cirka over kursen med 244,3 %. Af 10 analytikere anbefaler 9 køb — den samlede vurdering er Køb.
Crossject aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Crossject aktie og aktieanalyse
Hyppigt stillede spørgsmål om Crossject-aktien
The business model of Crossject SA revolves around the development and commercialization of innovative drug delivery systems. Crossject specializes in needle-free, self-administered emergency treatments for severe medical conditions such as anaphylactic shock and epileptic seizures. The company's proprietary technology, Zeneo®, enables the rapid and efficient delivery of drugs through the skin, ensuring quick and reliable therapy in critical situations. By combining ease of use, portability, and safety, Crossject aims to revolutionize the field of self-medication. With a focus on achieving market penetration globally, Crossject collaborates with pharmaceutical companies to expand the range of emergency treatments available through its innovative delivery platform.
Crossject SA is primarily active in the pharmaceutical industry.
The main competitors of Crossject SA in the market include companies such as Pfizer, Novartis, Eli Lilly, Sanofi, and Johnson & Johnson.
Crossject SA is a renowned pharmaceutical company that specializes in developing innovative and efficient medical solutions. Founded in [year], the company is based in [location] and has a rich history of successful product development. Crossject SA primarily focuses on the development of advanced and easy-to-use medical injection systems, which aim to enhance patient convenience and treatment experiences. With a strong commitment to research and development, Crossject SA collaborates with experts in the healthcare industry to bring cutting-edge solutions to the market. The company has gained a reputation for its dedication to improving medical delivery methods, ensuring safer and more effective treatments for patients worldwide.
Crossject SA has achieved several significant milestones. The company successfully developed an innovative and proprietary needle-free injection system, Zeneo®. This device has the potential to revolutionize the way drugs are administered, providing numerous benefits such as painless injections, rapid drug delivery, and ease of use. Furthermore, Crossject SA has obtained regulatory approval for Zeneo® in Europe and initiated partnerships with major pharmaceutical companies to develop and market various drugs using their advanced technology. These achievements highlight Crossject SA's commitment to revolutionizing drug delivery and position the company as a key player in the pharmaceutical industry.
Crossject SA is primarily present in France, its country of origin. As a biopharmaceutical company, it focuses on developing and commercializing innovative injectable drug device combinations. With its headquarters in Dijon, France, Crossject SA operates in the European Union and has a strong presence in other regions as well. Its mission is to improve the quality of life for patients through its needle-free injection technologies.
Crossject SA represents a set of core values and a corporate philosophy that aligns with their mission. Known for their innovative drug delivery solutions, Crossject SA emphasizes excellence, integrity, and patient-centricity. With a focus on developing needle-free injection systems, the company is committed to providing safe, convenient, and effective medical devices to improve patient outcomes. Crossject SA's corporate philosophy centers around technological advancement, collaboration, and market leadership. Through their dedication to research, development, and strategic partnerships, Crossject SA continues to push boundaries in the pharmaceutical industry, delivering innovative solutions and driving positive change for patients globally.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 4,11 EUR for Crossject-aktien (median: 4,39 EUR), svarende til +228,1 % i forhold til seneste kurs. Konsensus bygger på 10 analytikervurderinger.
10 analytikere vurderer i øjeblikket Crossject-aktien: 9 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at Crossject genererer omsætning på 34,50 Mio. EUR og indtjening pr. aktie på -0,02 EUR.
Crossject-aktien (ALCJ.PA) er noteret på 3 børser, herunder: Frankfurt (74C.F), Paris (ALCJ.PA).
Crossject SA is an innovative healthcare company based in France that specializes in the development and manufacturing of injectable drug systems. The company aims to create new solutions for fast, easy, and safe drug administration. Crossject has been listed on the stock market since 2014 and has branches in France, Switzerland, and the USA. The business model of Crossject is based on the development and commercialization of innovative autoinjectors that contribute to improving the treatment of chronic and acute diseases. The company focuses on four main areas: diabetes, anaphylaxis, pain management, and emergency medicine. Crossject is currently developing a range of products in these areas that meet the requirements of patients, doctors, and hospitals. The products offered by Crossject include the ZMI Autoinjector System, the ZENEO Autoinjector System, and the COLLECTJECT Autoinjector System. The ZMI Autoinjector System is an easy-to-use system that administers medications in precise doses. This system is ideal for diabetics and provides a fast and effective solution for insulin administration. The ZENEO Autoinjector System has been specifically designed for use in patients with anaphylaxis. It is easy to use and provides fast and precise administration of adrenaline. The COLLECTJECT Autoinjector System is a disposable autoinjector specifically designed for emergencies. It can be used to administer various medications such as painkillers and antibiotics. Crossject's core competence is its proprietary Needle Free Injection technology, which allows for the administration of medications without penetrating the skin with a needle. This technology is not only efficient and painless, but also reduces the risk of needlestick injuries and infections. Crossject has successfully integrated this technology into its autoinjectors and is currently able to offer a variety of medications in injectable form. Crossject has developed a comprehensive strategy for the commercialization of its autoinjectors. The company works closely with its customers to better understand the needs of patients and doctors and adapt its products accordingly. Crossject has also formed partnerships with major pharmaceutical companies such as Sanofi and CDM Lavoisier to market its products and build a global presence. Overall, Crossject's business model demonstrates that the company is innovative and focused on the needs of patients and doctors. Crossject aims to revolutionize the healthcare industry through the development of new autoinjectors and the introduction of new medications. The company also strives to expand its global presence and strengthen its partnerships with pharmaceutical companies to better market its products.
forventet-omsætningen for Crossject er 34,50 Mio. EUR. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Crossject er -827.310,70 EUR. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Crossject er i øjeblikket -80,48. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Crossject-aktien.
Pris-til-salgs-forholdet (P/S) for Crossject er i øjeblikket 1,93. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Crossject-aktien.
AlleAktien-kvalitetsscore for Crossject er 2/10.
ISIN for Crossject er FR0011716265. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Crossject er A1XEH4. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Crossject er ALCJ.PA. Tickersymbolet bruges til at handle Crossject-aktier på børsen.
Crossject aktie
Alle fundamentale data om Crossject i deep dive
Vores aktieanalyse af Crossject-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Crossject. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: